Navigation Links
Mylan Reports a 23% Increase in Fourth Quarter 2012 Adjusted Diluted EPS to $0.65
Date:2/27/2013

Mylan uses such a non-GAAP measure, it will provide a reconciliation of non-GAAP financial measures to the most closely applicable GAAP financial measure. Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most closely applicable GAAP measure set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP.

Below is a reconciliation of GAAP net earnings attributable to Mylan Inc. and diluted GAAP EPS to adjusted net earnings attributable to Mylan Inc. and adjusted diluted EPS for the three months and years ended December 31, 2012 and 2011 (in millions, except per share amounts): Three Months Ended December 31,Year Ended December 31,2012201120122011GAAP net earnings attributable to Mylan Inc. and diluted GAAP EPS

$
2.0$
.39$
29.5$
.30$
40.9$
.52$
536.8$
.22Purchase accounting related amortization (included in cost of sales) (a)

88.086.8391.1364.8Litigation settlements, net

(1.0)20.1(3.0)48.6Interest expense, primarily amortization of convertible debt discount

7.613.035.649.8Non-cash accretion and fair value adjustments of contingent consideration liability

7.7—38.7—Clean energy investment pre-tax loss (b)

4.4—16.8—Financing related costs (included in other income (expense), net)

—34.0—34.0Restructuring and other special items included in:Cost of sales

15.00.865.78.4Research and development expense

5.40.612.43.6Selling, general and administrative expense

39.28.1104.944.9Other income, net

(1.7)1.4(0.7)0.2Tax effect of the above items and other income tax related items

(59.7)(67.7)(215.7)(198.1)Adjusted net earnings attributable to Mylan Inc. and adjusted diluted EPS
'/>"/>

SOURCE Mylan Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine technology :

1. Mylan Launches Innovative Portfolio of Antiretroviral Products for Treatment of HIV/AIDS in South Africa
2. Mylan Enhances Partnership with Biocon through Strategic Collaboration for Insulin Products
3. Mylan Schedules Fourth Quarter and Year End 2012 Financial Results Conference Call and Live Webcast
4. Mylan Appoints Melina Higgins and Rajiv Malik to Board of Directors
5. Mylan Announces Pricing of Senior Notes
6. Moodys and Standard & Poors Upgrade Mylan to Investment Grade Credit Ratings
7. Mylan Reports a 51% Increase in Third Quarter 2012 Adjusted Diluted EPS to $0.83
8. Mylan Selected as a Leading ARV Supplier to Indias National AIDS Control Organization
9. Pfizer and Mylan Team Up to Establish Exclusive Long-Term Strategic Collaboration to Drive Sustained Growth of Generics Business in Japan
10. Mylan Launches Lithium Carbonate Extended-Release Tablets USP
11. Mylan Launches Commercial Operations in India, Starting with a Broad, Innovative Portfolio of ARV Products to Treat HIV/AIDS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... 2015  SurgiQuest®, Inc. ("SurgiQuest", the "Company"), a ... invasive surgery (MIS) announced today that surgeons have ... procedures.  Adoption has risen rapidly with a 150% ... by the company,s expansion from robotics into the ... to over 45 countries.   The ...
(Date:6/3/2015)... , June 02, 2015 Research and ... of the "Global Neurodegenerative Diseases Market 2015-2019" ... global neurodegenerative diseases market to grow at a ... This report covers the present scenario and ... market for the period 2015-2019. To calculate the ...
(Date:6/3/2015)... 2015  EIP Pharma LLC ( www.eippharma.com ) today ... of VX-745 in Alzheimer,s disease (AD) is underway.  VX-745 ... inhibitor of the alpha isoform of the protein enzyme ... "Recent human genetic data demonstrate that inflammation is ... Alzheimer,s, while the science also indicates the p38 MAPK ...
Breaking Medicine Technology:Rapid Procedure Growth With SurgiQuest's AirSeal System 2Global Neurodegenerative Diseases Market 2015-2019 - Reformulation of Marketed Drugs 2EIP Pharma announces first patient dosing in phase 2 clinical studies of a novel brain-targeted anti-inflammatory drug candidate, VX-745, for the treatment of Alzheimer's disease (AD) 2EIP Pharma announces first patient dosing in phase 2 clinical studies of a novel brain-targeted anti-inflammatory drug candidate, VX-745, for the treatment of Alzheimer's disease (AD) 3
... Inc. ( www.bendresearch.com ), a leading independent drug-formulation development and ... Jim Nightingale, who has worked at the company since 1993, ... Nightingale will succeed Rod Ray, who will ... (CEO) and chairman of the board of directors. ...
... Mass., July 27, 2011 Magellan Biosciences, a ... testing easier, more cost-effective, and less labor intensive, ... Atlanta yesterday at the AACC Clinical Lab Expo. ... laboratories seeking to improve the workflow efficiency, cost-effectiveness, ...
Cached Medicine Technology:Bend Research Inc. Names New President 2Magellan's Dynex® Agility™ ELISA Processor Dramatically Reduces Laboratory Time and Labor in Diagnostic Testing While Ensuring the Most-Accurate Results 2Magellan's Dynex® Agility™ ELISA Processor Dramatically Reduces Laboratory Time and Labor in Diagnostic Testing While Ensuring the Most-Accurate Results 3
(Date:6/3/2015)... PINES, FL (PRWEB) June 03, 2015 The ... event as part of the Veterans Health Administration’s (VHA) National ... place in the JC Cobb room located on the first ... 10:00 a.m. to 4:00 p.m. Women Veterans and their ... are invited to attend. To download a printable event flyer, ...
(Date:6/3/2015)... Norcross, GA (PRWEB) June 03, 2015 ... officially named the winner of its 2015 U.S. Education ... Power Portfolio in a college or university in the ... a GIScience student focused on Remote Sensing and Civil ... winning study, titled, “Pavement Surface Cracks Detection and Assessment ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 Johnson & ... pay $7.8 million to resolve a Risperdal lawsuit ( ... tactics the company allegedly used to market the antipsychotic ... Court indicate that the Arkansas Attorney General moved to ... the accord. The Risperdal settlement amounts to just a ...
(Date:6/3/2015)... 2015 On June 22, 2015, Medicare ... drug sensitivity (pharmacogenetic) testing that it has reimbursed since 2009. ... as 19 million of the 49 million Medicare beneficiaries in ... life-threatening adverse drug events.(1) Sadly, if it became a standard ... Medicine, the use of an individual’s genetic information to tailor ...
(Date:6/3/2015)... Array Health , a leading ... that CEO Jonathan Rickert will present at America’s ... 4, 2015. The session will address the how the ... business models in health care, and why they are ... Digital Transformation and the Health Care Enterprise: Driving Business ...
Breaking Medicine News(10 mins):Health News:Bay Pines to Host National Women Veterans Campaign Event June 12 2Health News:Bay Pines to Host National Women Veterans Campaign Event June 12 3Health News:Hexagon Geospatial Announces U.S. Education Challenge Winner at HxGN Live 2015 2Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 2Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 3Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 4Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 2Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 3Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 4Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 5Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 6Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 7Health News:Array Health’s CEO to Present at America’s Health Insurance Plans Institute 2015 2
... the pain-balm segment, with a market share of 70 ... Amrutanjan, Tiger Balm (locally manufactured by Elder Pharma), Zandu ... SmithKline India (GSK) has decided to transfer its Iodex ... a GSK subsidiary. SKBCH has a strong marketing and ...
... the most common cancer among women. It accounts for ... more than 23,000 new cases diagnosed in 2001. Progestin ... the highest// level of protection against ovarian cancer. Analysis ... study showed that the pill can help prevent ovarian ...
... disease that affects at least 39 million Americans, and ... to describe the problem. One in five Americans is ... raises the risk of many potentially fatal health conditions//, ... is linked to at least 300,000 deaths in the ...
... studying eight cross-gender heart transplants from New York Medical ... the heart after injury.// The research explodes the long-standing ... finding has implications for heart disease treatment. ... damaged heart much as it does other organs came ...
... non-steroidal anti-inflammatory drug (NSAID) treatment has shown that ... the risk of ulcer formation.// Treatment with omeprazole ... infections and reduced the six-month ulcer probability of ... to 12 per cent in the NSAID-treated arthritis ...
... discovered molecules in the body that can protect ... research, the research could potentially lead to the ... been linked with ailments such as cardiovascular disease, ... and Alzheimer’s disease. ,The researchers from ...
Cached Medicine News:
With the Symphony family of Pacemakers, Ela presents the most advanced technology on the market. Symphony, lighter than a passport, will take your patients further, offering fast follow-up, using new...
Gentle curve facilitates less traumatic removal from eye. Increased length ideal for myopic eyes...
Sleeve extends 3mm beyond end, .90mm (20G) probe, 1.4mm (17G) sleeve...
Ideal for short scleral tunnel and trabecular meshwork incisions...
Medicine Products: